Sponsor
Merck Sharp & Dohme
123 PBAC submissions on file, active 2006–2025. 79% have been recommended.
Submissions
123
2006 → 2025
Win rate
79 %
97 recommended of 123 bucketable
Drugs
47 · 38 listed
unique molecules submitted
PBS spend captured
$1.13B
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Oncology 55 Endocrinology 13 Cardiovascular 11 Infectious disease 11 Rheumatology 9 Hepatology 7 Haematology 3 Women's health 2 Vaccines 2 Respiratory 2
Activity by year 2006 (4) · 2007 (1) · 2008 (4) · 2009 (2) · 2010 (2) · 2011 (6) · 2012 (9) · 2013 (4) · 2014 (4) · 2015 (6) · 2016 (10) · 2017 (11) · 2018 (17) · 2019 (9) · 2020 (9) · 2021 (5) · 2022 (5) · 2023 (6) · 2024 (2) · 2025 (7)
Rejection patterns
Across 23 Not recommended decisions on file.
2× concerns over labelling and packaging of co-pack and risk of incorrect use by patients1× Complex restrictions require full written assessment1× treatment failure exemption falls outside biosimilar uptake measures agreed under Strategic Agreements1× contemporary clinical evidence does not support biosimilar exemption from treatment failure rule1× No economic analysis providedOpen on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.